such an approach holds promise for decreasing the expense associated with antibody use and the dose-related toxicity associated with dhpg use while maintaining or possibly increasing the efficacy of prophylaxis and therapy of serious cmv disease in humans .
C0017066
dhpg
C0010823
cmv disease